274.48
Praxis Precision Medicines Inc stock is traded at $274.48, with a volume of 75,992.
It is up +0.81% in the last 24 hours and up +62.03% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$272.92
Open:
$273
24h Volume:
75,992
Relative Volume:
0.08
Market Cap:
$6.87B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-29.93
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-0.46%
1M Performance:
+62.03%
6M Performance:
+549.79%
1Y Performance:
+259.54%
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines Inc
|
274.91 | 6.82B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.22 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.00 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
410.70 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.66 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.99 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Aug Wrap: Why Praxis Precision Medicines Inc. stock could be next big winnerMarket Risk Analysis & Fast Entry High Yield Tips - ulpravda.ru
Praxis Precision Medicines (PRAX) Price Target Increased by 38.02% to 410.52 - Nasdaq
Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
What dividend safety score for Praxis Precision Medicines Inc. stock2025 Earnings Impact & Free Community Consensus Stock Picks - Улправда
Can Praxis Precision Medicines Inc. stock continue upward trendChart Signals & Daily Growth Stock Investment Tips - ulpravda.ru
Why Praxis Precision Medicines Inc. stock appeals to dividend seekersTrade Performance Summary & High Conviction Trade Alerts - Улправда
Can Praxis Precision Medicines Inc. stock beat market expectations this quarterDollar Strength & Advanced Technical Analysis Signals - DonanımHaber
How strong is Praxis Precision Medicines Inc. stock balance sheetJuly 2025 Movers & Fast Gain Stock Trading Tips - DonanımHaber
How Praxis Precision Medicines Inc. stock benefits from global expansionWeekly Trade Report & Weekly Top Stock Performers List - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesSwing Trade & Daily Technical Forecast Reports - Bölüm Sonu Canavarı
Why Praxis Precision Medicines Inc. stock could be next big winner2025 Fundamental Recap & AI Enhanced Trading Signals - Улправда
Medical Stocks To Follow NowDecember 5th - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 279.0 USD - Investing.com India
Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something - Yahoo Finance
Oppenheimer Maintains Praxis Precision Medicines (PRAX) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Praxis Precision Medicine (P - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighWhat's Next? - MarketBeat
Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating - marketscreener.com
Praxis Precision Medicines stock hits 52-week high at 279.0 USD By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer - Investing.com Australia
Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer By Investing.com - Investing.com South Africa
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Praxis Precision Medicines Plans New Drug Application - The Globe and Mail
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Praxis Precision Medicines (PRAX): Revisiting Valuation After Major FDA Progress and Positive CNS Trial Updates - Sahm
Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN
Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative
TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN
Praxis Precision Medicines Announces Plans to File an NDA - GlobeNewswire
TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey
HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN
Velan Capital Investment Management LP Sells 35,666 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Maven Securities LTD Buys Shares of 5,000 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Says FDA Agrees to Proposed Changes to Embrave3 Trial Design - marketscreener.com
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision Medicines Announces Alignment with FDA on - GlobeNewswire
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):